457 related articles for article (PubMed ID: 37016182)
21. Meningioma and hormonal influences.
Wahab M; Al-Azzawi F
Climacteric; 2003 Dec; 6(4):285-92. PubMed ID: 15006250
[TBL] [Abstract][Full Text] [Related]
22. The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma.
Zhu H; Miao Y; Shen Y; Guo J; Xie W; Zhao S; Dong W; Zhang Y; Li C
J Transl Med; 2019 Oct; 17(1):354. PubMed ID: 31665029
[TBL] [Abstract][Full Text] [Related]
23. Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase.
Johnson MD; Woodard A; Okediji EJ; Toms SA; Allen GS
J Neurooncol; 2002 Jan; 56(2):133-42. PubMed ID: 11995814
[TBL] [Abstract][Full Text] [Related]
24. Emerging systemic treatment options in meningioma.
Mair MJ; Berghoff AS; Brastianos PK; Preusser M
J Neurooncol; 2023 Jan; 161(2):245-258. PubMed ID: 36181606
[TBL] [Abstract][Full Text] [Related]
25. Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics.
Kar R; Dhar R; Mukherjee S; Nag S; Gorai S; Mukerjee N; Mukherjee D; Vatsa R; Chandrakanth Jadhav M; Ghosh A; Devi A; Krishnan A; Thorat ND
ACS Biomater Sci Eng; 2023 Feb; 9(2):577-594. PubMed ID: 36621949
[TBL] [Abstract][Full Text] [Related]
26. Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
Maze EA; Agit B; Reeves S; Hilton DA; Parkinson DB; Laraba L; Ercolano E; Kurian KM; Hanemann CO; Belshaw RD; Ammoun S
Cancer Res; 2022 Jan; 82(2):235-247. PubMed ID: 34853069
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy and targeted therapies for meningiomas: what is the evidence?
Graillon T; Tabouret E; Chinot O
Curr Opin Neurol; 2021 Dec; 34(6):857-867. PubMed ID: 34629433
[TBL] [Abstract][Full Text] [Related]
28. Antiestrogenic therapy of meningiomas--a pilot study.
Markwalder TM; Seiler RW; Zava DT
Surg Neurol; 1985 Sep; 24(3):245-9. PubMed ID: 4023903
[TBL] [Abstract][Full Text] [Related]
29. Recent progresses in exosome-based systems for targeted drug delivery to the brain.
Bashyal S; Thapa C; Lee S
J Control Release; 2022 Aug; 348():723-744. PubMed ID: 35718214
[TBL] [Abstract][Full Text] [Related]
30. Exosomes as Tools to Suppress Primary Brain Tumor.
Katakowski M; Chopp M
Cell Mol Neurobiol; 2016 Apr; 36(3):343-52. PubMed ID: 26983831
[TBL] [Abstract][Full Text] [Related]
31. A vivid outline demonstrating the benefits of exosome-mediated drug delivery in CNS-associated disease environments.
Ray R; Chowdhury SG; Karmakar P
Arch Biochem Biophys; 2024 Mar; 753():109906. PubMed ID: 38272158
[TBL] [Abstract][Full Text] [Related]
32. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
[TBL] [Abstract][Full Text] [Related]
33. The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review.
Scerrati A; Mongardi L; Visani J; Lofrese G; Cavallo MA; Fiorentino A; De Bonis P
Expert Rev Anticancer Ther; 2020 Mar; 20(3):197-203. PubMed ID: 32116057
[No Abstract] [Full Text] [Related]
34. Methylation status of MGMT gene promoter in meningiomas.
de Robles P; McIntyre J; Kalra S; Roldán G; Cairncross G; Forsyth P; Magliocco T; Hamilton M; Easaw J
Cancer Genet Cytogenet; 2008 Nov; 187(1):25-7. PubMed ID: 18992637
[TBL] [Abstract][Full Text] [Related]
35. Synergistic inhibitory effects of interferon-alpha and 5-fluorouracil in meningioma cells in vitro.
Zhang ZJ; Wang JL; Muhr C; Smits A
Cancer Lett; 1996 Feb; 100(1-2):99-105. PubMed ID: 8620460
[TBL] [Abstract][Full Text] [Related]
36. Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges.
Zhang M; Zang X; Wang M; Li Z; Qiao M; Hu H; Chen D
J Mater Chem B; 2019 Apr; 7(15):2421-2433. PubMed ID: 32255119
[TBL] [Abstract][Full Text] [Related]
37. Transforming Growth Factor Beta Family in the Pathogenesis of Meningiomas.
Johnson MD
World Neurosurg; 2017 Aug; 104():113-119. PubMed ID: 28344175
[TBL] [Abstract][Full Text] [Related]
38. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
[TBL] [Abstract][Full Text] [Related]
39. Drug Repositioning for Refractory Benign Tumors of the Central Nervous System.
Tamura R
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629179
[TBL] [Abstract][Full Text] [Related]
40. [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene].
Kunishio K; Kobayashi K; Kagawa M; Makabe T; Matsumoto A; Matsumoto Y
Gan To Kagaku Ryoho; 2007 Feb; 34(2):265-8. PubMed ID: 17301541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
